SLCTR/2018/021尚未招募3 期
Efficacy and safety of chelation therapy with Calcium Disodium EDTA in reducing the progression of Chronic Kidney Disease of unknown etiology in Sri Lanka- A Double blinded placebo controlled randomized controlled clinical trial
niversity of Colombo0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Males and females aged between 18 and 75 years
- •2. Stages 1-3 of chronic kidney disease of unknown origin
- •3. High cadmium body burden (urinary cadmium levels > 4.94ug per g of creatinine according to WHO/ FAO toxicokinetic model).
排除标准
- •1. Patients with acute myocardial infarction or stroke in the previous six months
- •2. Hypertension
- •3. Diabetes
- •4. Patients with cancers
- •5. Known cardiac arrhythmias
- •6. Seizures disorders
- •7. Known hypersensitivity to Calcium Disodium EDTA
- •8. Hypocalcaemia
- •9. Pregnancy and breast feeding
研究者
相似试验
已完成
2 期
Study of Ayurvedic drug Calciactiv for the treatment of bone weaknessCTRI/2017/08/009259Siddhayu Ayurvedic Research Foundation Pvt Ltd30
尚未招募
不适用
Effect of Vitamin D and turmeric in lymphoma patients.CTRI/2020/06/025818JIPMER Intramural fund
已完成
不适用
Combined oral iron chelation in thalassemiaCTRI/2018/02/012134JIPMER23
进行中（未招募）
不适用
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2010-018861-53-NLeiden University Medical Center
已完成
4 期
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatioprimary hyperparathyroidismhyperactive parathyroid glands1008362410033949NL-OMON34871eids Universitair Medisch Centrum20